TriSalus Life Sciences (TLSI) Total Liabilities (2020 - 2026)

TriSalus Life Sciences' Total Liabilities history runs 7 years deep, the most recent figure standing at $58.2 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 7.66% year-over-year to $58.2 million in Q1 2026; TTM through Mar 2026 was $58.2 million, a 7.66% decrease from a year earlier, with the FY2025 full-year figure at $69.2 million, up 38.76% from the prior year.
• Total Liabilities retreated to $58.2 million in Q1 2026 per TLSI's latest filing, from $69.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $69.2 million in Q4 2025 and bottomed at $12.0 million in Q2 2022.
• The 5-year median for Total Liabilities is $49.9 million (2024), against an average of $41.2 million.
• Across the five-year window, Total Liabilities sank 46.89% in 2022 and surged 271.65% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $34.3 million in 2022, then jumped by 50.54% to $51.7 million in 2023, then dropped by 3.48% to $49.9 million in 2024, then soared by 38.76% to $69.2 million in 2025, then fell by 15.93% to $58.2 million in 2026.
• Per Business Quant, the three latest TLSI Total Liabilities figures stand at $58.2 million (Q1 2026), $69.2 million (Q4 2025), and $63.2 million (Q3 2025).